Sano Chemicals

Funding to accelerate development of promising therapy for recurrent vulvovaginal candidiasis, a condition affecting millions of women worldwide

Sano Women's Health has received investigational new drug approval from the FDA, for Occidiofungin, a first-in-class novel peptide with broad antifungal activity.

Sano Chemicals today announced the start of a Phase 1, first-in-human clinical trial, of Occidiofungin, a new chemical entity under development as a treatment to cure recurrent vulvovaginal candidiasis (RVVC).